![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 43, 30887-30895, October 22, 1999
From the Departments of Cell Biology and Orthopedics, Yale
University School of Medicine, New Haven, Connecticut 06510
The 120-kDa proto-oncogenic protein c-Cbl is a
multidomain adaptor protein that is phosphorylated in response to the
stimulation of a broad range of cell surface receptors and participates
in the assembly of signaling complexes that are formed as a result of
the activation of various signal transduction pathways. Several structural features of c-Cbl, including the phosphotyrosine-binding domain, proline-rich domain, and motifs containing phosphotyrosine and
phosphoserine residues, mediate the association of c-Cbl with other
components of these complexes. In addition to those domains that have
been demonstrated to play a role in the binding of c-Cbl to other
signaling molecules, c-Cbl also contains a RING finger motif and a
putative leucine zipper. In this study, we demonstrate that the
previously identified putative leucine zipper mediates the formation of
Cbl homodimers. Using the yeast two-hybrid system, we show that
deletion of the leucine zipper domain is sufficient to abolish Cbl
homodimerization, while Cbl mutants carrying extensive N-terminal
truncations retain the ability to dimerize with the full-length Cbl.
The requirement of the leucine zipper for the homodimerization of Cbl
was confirmed by in vitro binding assays, using deletion
variants of the C-terminal half of Cbl with and without the leucine
zipper domain, and in cells using Myc and green fluorescent protein
(GFP) N-terminal-tagged Cbl variants. In cells, the deletion of the
leucine zipper caused a decrease in both the tyrosine phosphorylation
of Cbl and its association with the epidermal growth factor receptor
following stimulation with epidermal growth factor, thus demonstrating
a role for the leucine zipper in c-Cbl's signaling functions. Thus,
the leucine zipper domain enables c-Cbl to homodimerize, and
homodimerization influences Cbl's signaling function, modulating the
activity of Cbl itself and/or affecting Cbl's associations with other
signaling proteins in the cell.
Characterization of the mechanisms by which multiprotein signaling
complexes are assembled around or downstream of activated cell surface
receptors is essential for understanding how signal transduction
pathways operate. In addition to receptor and nonreceptor tyrosine
kinases and their substrates, adaptor proteins, with their specialized
modular domains, participate in the assembly of such multiprotein
complexes, recruiting signaling molecules into specific networks (1).
Accumulating experimental data indicates that the c-Cbl protein is such
an adaptor molecule, with diverse binding domains that contribute to
the assembly of signaling complexes involved in various signal
transduction pathways (2-4). c-Cbl is a 120-kDa cytosolic protein that
was originally identified as a cellular homologue of transforming
v-Cbl, an extensively C-terminally truncated form of Cbl that is
implicated in the development of pre-B cell lymphomas and myelogenous
leukemias in mice (5, 6). It is ubiquitously expressed, with the
highest levels found in cells of hematopoietic origin (6).
c-Cbl has been shown to be a major substrate of protein-tyrosine
kinases following activation of a broad range of cell surface receptors. Thus, tyrosine-phosphorylation of c-Cbl has been
demonstrated in response to
EGF,1 platelet-derived growth
factor, fibroblast growth factor, nerve growth factor,
colony-stimulating factor-1, granulocyte-macrophage colony-stimulating
factor, and erythropoietin, as well as upon the stimulation of the
Fc However, c-Cbl is a multidomain protein with many potential binding
sites that can mediate protein associations through mechanisms other
than phosphotyrosine- or phosphoserine-dependent
interactions. Domains of c-Cbl that have been demonstrated or predicted
to be engaged in protein associations include a RING finger in the
middle of the molecule, an extensive proline-rich region in the
C-terminal half of the protein, and a putative leucine zipper at the C
terminus (6). Indeed, c-Cbl has been shown to associate through the proline-rich region with numerous Src homology 3 domain-containing proteins, including the adaptor molecules Grb2 and Nck and the protein
kinases Fyn, Lyn, Lck, Src, and Bruton's tyrosine kinase (7, 9,
16-18, 20, 26-28). While no involvement of the RING finger of c-Cbl
in protein interactions has yet been reported, it is known that small
deletions or point mutations in this region activate the transforming
potential of c-Cbl (6), and we have found that this domain binds the
ubiquitin-conjugating protein UbcH7.2 Furthermore, the
N-terminal half of c-Cbl contains a nuclear localization signal that
could play a role in the transforming activity of v-Cbl (6).
Together, these findings point to an important general role of c-Cbl in
signaling downstream of cellular receptors coupled to tyrosine kinases,
but specific biological functions of this molecule remain unclear.
Recent reports indicate, however, that c-Cbl has the ability, through
direct interactions, to regulate the function of signaling proteins.
Based on genetic studies, SLI-1, the homologue of Cbl in
Caenorhabditis elegans, was identified as a negative
regulator of the LET-23 receptor tyrosine kinase, the homologue of the
mammalian EGF receptor (29). A similar regulatory function has been
postulated for D-Cbl, the Drosophila homologue of Cbl (30).
In mammalian cells, expression of transforming mutants of Cbl (v-Cbl
and 70Z-Cbl) up-regulates the signaling through platelet-derived growth
factor receptor All of these earlier studies have focused on the interactions of c-Cbl
with other signaling proteins but have not considered the possibility
of its self-association. Some of c-Cbl's protein-binding domains, such
as a RING finger and a putative leucine zipper, are, however, known to
mediate the formation of homodimers in other proteins. We therefore
examined the ability of human c-Cbl to homodimerize using a number of
in vivo and in vitro methodologies and found that
Cbl homodimerizes through its leucine zipper domain. This ability to
dimerize was found to be necessary for the efficient EGF-induced
tyrosine phosphorylation of Cbl and its association with EGFR, and it
is likely to have other important implications for the biological
function of c-Cbl.
DNA Constructs--
Plasmids containing full-length c-Cbl and
various c-Cbl mutants were constructed based on the clone of HA-tagged
human c-Cbl in pGEM-4Z, kindly provided by Dr. W. Langdon (Department
of Biochemistry, University of Western Australia). Standard polymerase
chain reaction and DNA manipulation techniques were used to prepare the
constructs (34). The sequence of all polymerase chain reaction products was verified by DNA sequence analysis, and in addition, restriction analysis was performed on all of the plasmids used in this study. c-Cbl
constructs were first inserted in frame into the
BamHI/SalI sites of pET-28c vector (Novagen), to
allow expression of T7·Tag-Cbl fusion proteins. The c-Cbl inserts
were subsequently subcloned into BamHI/SalI sites
in pGex-5X-3 (Amersham Pharmacia Biotech), which were used to express
GST-Cbl fusion proteins. Additionally, c-Cbl constructs were inserted
into yeast expression vectors pBTM116 (BamHI/SalI
sites) and pVP16 (BamHI/NotI sites) (provided by
S. Hollenberg) for use in the two-hybrid assay. The following human c-Cbl constructs were prepared (Fig. 1; numbers in parentheses indicate
the amino acids of human c-Cbl included in the construct): full-length
c-Cbl (2-906) (Cbl-FL); N-terminal half of c-Cbl (2-450) (Cbl-N
half); C-terminal half of c-Cbl (479-906) (Cbl-C half); deletion of
leucine zipper domain from the full-length c-Cbl (2-856) (Cbl- Yeast Two-hybrid Assay--
The procedures of Vojtek et
al. (35, 36) and Hollenberg et al. (37) were followed
for growing, transforming, selecting, and mating the yeast strains. The
yeast strains L40 (MATa) and AMR 70 (MAT Stable and Transient Transfection of HEK293 Cells--
HEK293
cells (ATCC) were maintained in Eagle's minimum essential medium, Purification of Fusion Proteins--
T7·Tag-Cbl and GST-Cbl
fusion proteins were expressed in BL21(DE3) cells (Novagen) transformed
with pET-28c-Cbl and pGEX-5X-3-Cbl constructs, respectively.
T7·Tag-Cbl fusion proteins were isolated using His-Bind resin and the
His-Bind buffer kit supplied by Novagen following the manufacturer's
procedure for the purification under native conditions. Specifically,
500 ml of culture was induced with 1 mM
isopropyl-1-thio- Immunoprecipitations--
250 µg of cell lysate protein was
incubated overnight at 4 °C in mRIPA containing 0.5 µg of mouse
monoclonal c-Myc antibody (Santa Cruz Biotechnology) or green
fluorescent protein (GFP) antibody (CLONTECH) and
25 µl of protein G-Sepharose beads (Calbiochem). Beads were then
washed three times with mRIPA, and protein was analyzed by Western blotting.
Western/Far Western Blotting--
The following antibodies were
used: mouse monoclonal antibody (mAb) anti-phosphotyrosine (Upstate
Biotech), anti-c-Myc mAb (Santa Cruz Biotechnology), rabbit anti-EGFR
polyclonal antibody (Santa Cruz Biotechnology), anti-GFP mAb
(CLONTECH), anti-T7·Tag mAb (Novagen), and
horseradish peroxidase-conjugated anti-mouse IgG and anti-rabbit IgG
antibodies (Promega). Total cell lysates, immunoprecipitates, or
purified GST, GST-Grb2, and GST-Cbl fusion proteins (amounts indicated
in the figure legends) were heated for 10 min at 37 °C in standard
SDS-sample buffer and separated on 10% SDS-polyacrylamide gels.
Proteins were then transferred to nitrocellulose membranes (BA85; pore
size, 0.45 µm) (Schleicher & Schuell), and the filters were incubated
for 2 h at room temperature in 5% milk, TBST buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween
20). For Far Western blots, filters were probed with purified
T7·Tag-Cbl fusion proteins at a concentration of 2 µg/ml in 2%
bovine serum albumin, TBST, 1 mM dithiothreitol for 1 h at room temperature, washed extensively five times with TBST
containing 0.3% Tween 20, and then analyzed by sequential incubation
with mAb anti-T7·Tag (1:10,000 dilution) and horseradish
peroxidase-conjugated anti-mouse IgG antibody (1:20,000 dilution) in
2% bovine serum albumin, TBST for 30 min each. Immunoprecipitations
and total cell lysates were visualized by immunoblotting with the
appropriate primary antibody (1:1000 dilution) and then a horseradish
peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG antibody. All
blots were developed using enhanced chemiluminescence reagents from
Amersham Pharmacia Biotech. To verify the quality of all blots,
proteins were visualized on the filters by staining with 0.2% Ponceau
S in 3% trichloroacetic acid.
In Vitro Binding--
Purified GST and GST-Cbl fusion proteins
(1 or 2 µg, as indicated in the figure legends) were bound to
glutathione-Sepharose 4B (Amersham Pharmacia Biotech) by agitation on
the rocking plate for 2 h at 4 °C in 0.5 ml of HNTG buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% glycerol,
0.1% Triton X-100) containing 1% bovine serum albumin and 1 mM dithiothreitol with or without competing T7·Tag-Cbl-LZ
fusion protein. At this time, the test T7·Tag-Cbl fusion protein was
added to the tubes, and the incubation continued for 1.5 h at room
temperature. Beads were washed three times with 1 ml of HNTG containing
1% Triton X-100 and boiled in SDS-sample buffer, and the samples were
electrophoresed on 12% SDS-polyacrylamide gel. Proteins were
transferred to nitrocellulose filters and blotted with mAb
anti-T7·Tag as for Far Western blotting.
For the two-hybrid assay, full-length c-Cbl and mutant variants of
c-Cbl were fused to both the LexA DNA binding domain and the
transcription activation domain of the VP16 protein, and pairs of
LexA-Cbl and VP16-Cbl hybrid proteins were coexpressed in yeast. The
binding of two hybrid proteins to each other results in transactivation of two reporter genes: the yeast HIS3 gene and the bacterial
lacZ gene, which are driven by promoters fused to multiple
binding sites for LexA. Binding is therefore detected by the growth of yeast in the medium lacking histidine and by induction of the activity
of We first tested the ability of full-length human c-Cbl (Cbl-FL) to form
homodimers. Coexpression in yeast of the LexA-Cbl-FL and VP16-Cbl-FL
hybrid proteins resulted in both growth in the medium lacking histidine
and induction of high In order to identify the sequences in the C-terminal half that mediate
the homodimerization, we generated a series of mutants of c-Cbl (as
shown schematically in Fig. 1) in which specific domains localized
within the C-terminal half were deleted from the full-length Cbl
construct: Cbl- The results of the two-hybrid assay demonstrated that the sequences
present within the putative leucine zipper domain at the C terminus of
Cbl are responsible for the ability of the protein to form homodimers.
In order to examine the role of the leucine zipper in homodimerization
in more detail, we then analyzed the interaction of full-length Cbl,
expressed as LexA-Cbl-FL fusion, with various deletion mutants and
short domains of Cbl, expressed as fusions with VP16. As shown in Fig.
3, all of the C-terminally truncated Cbl
mutants, Cbl-
Leucine Zipper-mediated Homodimerization of the Adaptor
Protein c-Cbl
A ROLE IN c-Cbl's TYROSINE PHOSPHORYLATION AND ITS ASSOCIATION
WITH EPIDERMAL GROWTH FACTOR RECEPTOR*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
receptor, T and B cell antigen receptors, c-Kit, integrins, and
receptors for interferon
, interleukin-3, insulin, and prolactin
(6-15). Furthermore, tyrosine phosphorylation of Cbl has been also
observed in v-Src-, v-Abl-, and BCR-Abl-transformed cells (6, 7, 16).
These tyrosine phosphorylation events may then lead to c-Cbl's
incorporation into molecular assemblies through the binding of the
phosphorylated sequences to the Src homology 2 or
phosphotyrosine-binding (PTB) domains of a wide range of other
signaling molecules, as has been shown for Crk family members;
protein-tyrosine kinases Fyn, Lck, and Abl; the p85 subunit of PI
3-kinase; phospholipase C
; and the nucleotide exchange factor Vav
(2, 9, 16-21). Conversely, c-Cbl also contains a PTB domain in its
N-terminal half that binds to the activated ZAP-70 protein kinase and
phosphorylated EGF and platelet-derived growth factor receptors
(22-24). In addition to these phosphotyrosine-dependent interactions, stimulation of the T cell antigen receptor has been reported to induce serine phosphorylation of c-Cbl, which in turn results in the binding of c-Cbl to the members of the 14-3-3 family of
proteins (25).
, and the requirement for the PTB domain in this
process has been demonstrated (24). Similarly, the expression of
70Z-Cbl has been shown to induce increases in both tyrosine
phosphorylation and kinase activity of the EGF receptor (31).
Furthermore, overexpression of Cbl inhibits the activity of the Syk
nonreceptor tyrosine kinase, with which Cbl forms a complex (32).
Finally, the Cbl PTB domain has been found to bind to the in
vivo negative regulatory phosphorylation site of ZAP-70 (33).
Based on these data, the PTB domain-dependent role of Cbl
as a negative regulator of receptor and nonreceptor tyrosine kinases
has been postulated (33). Thus, c-Cbl may function both as a negative
regulator of tyrosine kinases and as a multifunctional adaptor protein.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
LZ);
deletion of acidic domain from the full-length c-Cbl (2-710 and
835-906) (Cbl-
Ac); deletion of both acidic and leucine zipper
domains from the full-length c-Cbl (2-689) (Cbl-
(Ac + LZ));
deletion of leucine zipper domain from C-terminal half of c-Cbl
(479-856) (Cbl-C half,
LZ); acidic and leucine zipper domains of
c-Cbl (679-906) (Cbl-Ac + LZ); acidic domain of c-Cbl (679-856) (Cbl-Ac); and leucine zipper domain of c-Cbl (829-906) (Cbl-LZ). For
transient transfection experiments, constructs for N-terminal Myc-tagged Cbl-FL and Cbl-
LZ were prepared by subcloning
BamHI/NotI fragments from the pET-28c vector into
pBK-CMV-Myc. For N-terminal tagging with enhanced green fluorescent
protein (EGFP), the Cbl-FL construct was subcloned into the
BamHI/NotI sites of the pEGFP-C2 vector
(CLONTECH).
) were transformed with
plasmids pBTM116, containing Cbl fused to LexA DNA binding domain, and
pVP16, containing Cbl fused to VP16 activation domain, respectively.
The expression of correctly sized LexA-Cbl and VP16-Cbl proteins in
yeast transformants was confirmed by Western blot analysis using c-Cbl
monoclonal antibody (Transduction Laboratories) and c-Cbl (C-15)
polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
To select for diploid growth, yeasts were grown for 3 days at 30 °C
on plates with synthetic medium lacking uracil, tryptophan, and leucine
(ura
, trp
, leu
), followed by
-galactosidase assays. To select
for the interaction of proteins by induction of the HIS3
gene, yeasts were restreaked on plates with synthetic medium lacking
uracil, tryptophan, leucine, lysine, and histidine (ura
, trp
,
leu
, lys
, his
), and the yeast growth was followed up to 7 days.
Interactions between LexA-Cbl fusion proteins and the VP16 activation
domain alone, and LexA-lamin (provided by S. Hollenberg) and VP16-Cbl
proteins served as negative controls.
-Galactosidase Assays--
For quantitative
-galactosidase
assay, yeast diploids were grown in synthetic medium lacking uracil,
tryptophan, and leucine (ura
, trp
, leu
), and the assay was
performed according to the published procedure (34). At least four
independent diploid transformants were assayed. The
-galactosidase
unit is defined as A420 × 103/min × ml × A600
(34). Yeast diploid colonies grown on the plates with synthetic medium,
ura
, trp
, leu
and ura
, trp
, leu
, lys
, his
were also
analyzed by
-galactosidase filter assay as described elsewhere (34,
36). At least five independent transformants for each mating
combination were analyzed.
modification (
-MEM) supplemented with 10% fetal calf serum, 100 units/ml penicillin, and 100 µg/ml streptomycin. Cells were
transfected for 5 h using LipofectAMINETM (Life
Technologies, Inc.) in
-MEM following the manufacturer's protocol.
A stable cell line expressing EGFP-Cbl-FL was established by
transferring cells into culture medium supplemented with 500 µg/ml
G418 (Life Technologies, Inc.) 72 h post-transfection. Cells were
then maintained in this medium until resistant colonies of cells were
formed (approximately 2 weeks) and subsequently pooled (>20 colonies).
The cells were then routinely maintained in culture medium supplemented
with 100 µg/ml G418. For Fig. 6, HEK293 cells stably expressing
EGFP-Cbl-FL were transiently transfected with pBK-Myc-Cbl constructs,
and after 72 h they were washed in ice-cold phosphate-buffered
saline and then lysed in modified radioimmune precipitation assay
(mRIPA) buffer (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 0.1% Nonidet P-40, 0.25% sodium deoxycholate, 10 µg/ml leupeptin, 10 µg/ml aprotonin, 1 mM sodium orthovanadate,
10 mM NaF, 1 µg/ml pepstatin, and 1 mM
phenylmethylsulfonyl fluoride). For Fig. 7, culture medium was changed
65 h post-transfection to
-MEM supplemented with 0.1% fetal
calf serum, and cells were cultured for an additional 36 h. Cells
were then treated with 100 ng/ml EGF or vehicle for 3 min at 37 °C,
washed with ice-cold phosphate-buffered saline, and lysed in mRIPA.
-D-galactopyranoside for 4 h, the binding of the fusion protein to His-Bind resin was performed in a
batchwise fashion for 2 h at 4 °C, and 0.1% Triton X-100 was
included in the buffer to reduce nonspecific binding. GST, GST-Grb2,
and GST-Cbl fusion proteins were purified from 500 ml of bacterial
culture induced with 0.2 mM
isopropyl-1-thio-
-D-galactopyranoside for 4.5 h,
basically following the procedure described elsewhere (34). Fusion
proteins were bound to glutathione-Sepharose 4B (Amersham Pharmacia
Biotech) by incubation batchwise on the rocking plate for 6 h at
4 °C, and the protein was eluted with 20 mM reduced glutathione (Sigma) in 50 mM Tris-HCl, pH 8.0, 2 mM EDTA, 1 mM dithiothreitol by gentle
agitation for 2 h at 4 °C. Protein concentration in the eluted
fractions was estimated using a Bio-Rad protein assay (Bio-Rad). Fusion
proteins were subsequently concentrated on Centricon concentrators
(Amicon), and the concentration of proteins was evaluated visually on
SDS-polyacrylamide gels stained with Coomassie Brilliant Blue R-250,
comparing with bovine serum albumin standards.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-galactosidase.
-galactosidase activity, indicating strong
homodimerization (Fig. 2, column 1). We next
examined whether the domain(s) of c-Cbl that are responsible for
homodimer formation reside in the N- or C-terminal half of the Cbl
molecule. For this purpose, constructs expressing the N-terminal half
(Cbl-N half) and the C-terminal half (Cbl-C half) (see Fig.
1) were tested for the homodimer
interaction in the two-hybrid assay. As shown in Fig.
2, yeast that coexpressed LexA-Cbl-N half
and VP16-Cbl-N half failed to grow on the his
plates or to express
-galactosidase, demonstrating that the N-terminal half of Cbl does
not have the capability to form homodimers and that deletion of
sequences in the C-terminal half abolished the homodimer interaction.
The dimerization of the C-terminal half could not be demonstrated
directly, however, since the coexpression of the LexA-Cbl-C half with
the VP16 protein alone activated both the HIS3 and
lacZ reporter genes, resulting in high backgrounds in both
assays. Thus, the Cbl-C half when fused to the LexA DNA binding domain
showed the properties of an activator of transcription, preventing its
use in a yeast two-hybrid assay.

View larger version (25K):
[in a new window]
Fig. 1.
Schematic representation of human c-Cbl
constructs used in this study. The following main features and
domains of c-Cbl are shown: nuclear localization signal
(NLS), PTB domain, RING finger (RF), proline-rich
domain, acidic domain, and putative leucine zipper (LZ).
Also, the names of the c-Cbl constructs, as used throughout, together
with the numbers of amino acid sequence included or deleted in the
construct, are indicated on the left. Abbreviations used are
as follows: FL, full length; LZ, leucine zipper;
Ac, acidic domain.
indicates deletion.

View larger version (45K):
[in a new window]
Fig. 2.
Leucine zipper domain-mediated
homodimerization of c-Cbl analyzed by in vivo yeast
two-hybrid assay. Cbl-FL and c-Cbl deletion mutants (Cbl-N half,
Cbl-
LZ, Cbl-
Ac, and Cbl-
(Ac + LZ) (as indicated in Fig. 1.)),
fused to the LexA DNA binding domain, were tested for the interaction
with the identical c-Cbl mutant fused to the VP16 activation domain. A
-galactosidase assay in yeast liquid cultures was performed as
described under "Experimental Procedures." Values reported are the
average of at least four independent pairs of transformants assayed.
Vertical bars represent S.E.
(Ac + LZ), in which both acidic and leucine zipper
domains were deleted; Cbl-
Ac, which lacked the acidic domain; and
Cbl-
LZ, which lacked the leucine zipper domain. Each construct was
fused to both LexA and VP16 for analysis of homodimerization in the
two-hybrid assay. As shown in Fig. 2, Cbl-
(Ac + LZ), which consists
of the N-terminal half and the proline-rich domain (see Fig. 1), did
not homodimerize, indicating that either the acidic domain or the
putative leucine zipper domain carries the sequences responsible for
homodimer formation. Cbl-
Ac, from which residues 711-834 were
deleted, showed an ability to form homodimers that was only slightly
weaker than the homodimerization of Cbl-FL, as evaluated by the levels of
-galactosidase activity and growth of yeast on the his
plates (Fig. 2). In contrast, deletion of only 50 amino acids at the C
terminus (Cbl-
LZ) was sufficient to abolish the homodimerization of
Cbl completely (Fig. 2). As noted above, this region of Cbl has been
previously defined as a putative leucine zipper domain, based on the
presence of six heptad repeats of hydrophobic amino acids (6). To
exclude the possibility that activation of reporter genes by some of
the Cbl constructs was a result of nonspecific protein interactions,
two kinds of negative control experiments were performed: 1) LexA-Cbl
fusion proteins were tested for the interaction with VP16 protein
itself, and 2) VP16-Cbl hybrids were coexpressed with LexA-lamin fusion
protein. None of the Cbl constructs presented in Fig. 2, including
Cbl-FL, induced growth in his
medium or
-galactosidase activity in
either of the controls. However, fragments of Cbl-C half that contained
the acidic domain, such as Cbl-C half,
LZ, Cbl-Ac + LZ, and Cbl-Ac
(see Fig. 1), like the complete Cbl-C half, behaved as transcription
activators when fused to LexA and therefore could not be tested for
homodimer interaction in the two-hybrid assay.
LZ, Cbl-
(Ac + LZ), and Cbl-N half, with the shortest
truncation being in Cbl-
LZ, failed to associate with Cbl-FL,
confirming that the leucine zipper domain is absolutely required in
order for the homodimer interaction to occur. In contrast, the two
N-terminally truncated Cbl mutants, even the small Cbl-Ac + LZ, which
consists of only the acidic and leucine zipper domains, had the ability
to dimerize with Cbl-FL (see Fig. 3), and these interactions were only
slightly weaker than that of the Cbl-FL homodimer. Furthermore,
deletion of the leucine zipper domain from Cbl-C half and Cbl-Ac + LZ
(Cbl-C half,
LZ and Cbl-Ac, respectively) was sufficient to abolish
the interaction with Cbl-FL. Finally, as expected, Cbl-
Ac interacted
strongly with Cbl-FL, with the activity of
-galactosidase being even
higher than that induced by Cbl-FL homodimer, indicating that deletion
of the acidic domain does not suppress the ability of the protein to
dimerize (Fig. 3). The results of the
-galactosidase assays
presented in Fig. 3 were confirmed by the analysis of yeast growth in
the his
medium. None of the VP16-Cbl variants tested for the
interaction with LexA-Cbl-FL were able to induce expression of the
lacZ or the HIS3 gene when coexpressed with
LexA-lamin.

View larger version (39K):
[in a new window]
Fig. 3.
The leucine zipper domain is required for the
dimerization of full-length c-Cbl with c-Cbl mutant variants in the
yeast two-hybrid assay. Cbl-FL fused to the LexA DNA binding
domain was assayed for binding to Cbl-FL and c-Cbl mutants: Cbl-
LZ;
Cbl-
Ac; Cbl-
(Ac + LZ); Cbl-N half; Cbl-C half; Cbl-C half,
LZ;
Cbl-Ac + LZ; and Cbl-Ac fused to the VP16 activation domain. The
two-hybrid assay was performed as described in the legend for Fig.
2.
Since the data from the two-hybrid assay indicated that the c-Cbl
protein has the ability to form homodimers when expressed in
vivo in yeast cells and that this interaction is leucine
zipper-mediated, we then investigated the homodimerization of Cbl by
using in vitro binding experiments with fusion proteins. For
this purpose, the C-terminal half of Cbl and various truncation mutants
of the C-terminal half, with and without the leucine zipper domain,
were expressed as fusion proteins with GST or T7·Tag, purified, and
then analyzed for direct interaction by Far Western blotting and in
in vitro binding assays with glutathione-Sepharose beads.
For Far Western blotting, GST-tagged fusion proteins containing the
C-terminal half of Cbl with or without the leucine zipper domain were
first separated on SDS-polyacrylamide gels and transferred to
nitrocellulose filters, and then the filters were probed with various
T7·Tag-containing Cbl mutants (Fig. 4).
GST-Grb2 and GST were included on the filters as control proteins. The
T7-tagged C-terminal half of Cbl (T7·Tag-Cbl-C half) bound to
GST-Cbl-C half but not to GST-Cbl-C half,
LZ (Fig. 4A,
compare lanes 3 and 4 with
lanes 5 and 6). When the blot was probed with the C-terminal half, which lacked the leucine zipper domain
(T7·Tag-Cbl-C half,
LZ), no binding to either GST-Cbl-C half or
GST-Cbl-C half,
LZ was observed, as shown in Fig. 4B (lanes 3-6). Thus, removing the leucine zipper
from either one of interacting partners abolished the homodimerization
(Fig. 4, A, lanes 5 and 6,
and B, lanes 3 and 4),
indicating that direct interaction of the C-terminal half of Cbl takes
place only when the leucine zipper domain is present in both binding
partners (Fig. 4A, lanes 3 and
4). Both T7·Tag-Cbl-C half and T7·Tag-Cbl-C half,
LZ
fusion proteins bound to GST-Grb2 (Fig. 4, A and
B, lane 2), which interacts with the
proline-rich region of Cbl through its Src homology 3 domain (9, 18,
20). No binding to GST alone was observed (Fig. 4, A and
B, lane 1). We also compared the
binding of the T7·Tag fusion protein containing only the acidic and
leucine zipper domains, T7·Tag-Cbl-Ac + LZ, with that of the fusion
protein containing only the acidic domain, T7·Tag-Cbl-Ac. As shown in
Fig. 4C (lanes 3 and 4),
only T7·Tag-Cbl-Ac + LZ was found to interact strongly with GST-Cbl-C
half. The interaction of T7·Tag-Cbl-Ac + LZ with GST-Cbl-C half,
LZ, although detectable, was much weaker (Fig. 4C,
lanes 5 and 6). No binding of
T7·Tag-Cbl-Ac to GST-Cbl-C half or to GST-Cbl-C half,
LZ was
observed (Fig. 4D, lanes 3-6). These
results further confirmed that the leucine zipper domain must be
present on both binding partners in order for the interaction to take
place. As expected, neither T7·Tag-Cbl-Ac + LZ nor T7·Tag-Cbl-Ac
bound to GST-Grb2, since these two proteins lack the proline-rich
region of Cbl (Fig. 4, C and D, lane
2). Finally, we also tested the interaction of
T7·Tag-Cbl-LZ, which contains only 28 amino acids upstream of the
leucine zipper in addition to the 50 amino acids of the leucine zipper
itself (see Fig. 1), with GST-Cbl fusion proteins. T7·Tag-Cbl-LZ
bound to GST-Cbl-C half but not to GST-Cbl-C half,
LZ (Fig.
4E, lanes 2-4 versus
lanes 5-7). However, the T7·Tag-Cbl-LZ bound
to the GST-Cbl-C half much more weakly then the two other longer
T7-tagged fusion proteins, T7·Tag-Cbl-C half and T7·Tag-Cbl-Ac + LZ, since larger amounts of the GST fusion protein on the filter and
longer exposure times were necessary in order to get the same intensity of the bands on the blots.
|
Dimerization of Cbl Fusion Proteins Can Be Competitively Inhibited
by a Leucine Zipper Fusion Protein--
To provide further evidence of
an in vitro association, we investigated the interaction in
solution of GST-Cbl proteins with T7·Tag-Cbl fusion proteins. GST-Cbl
fusion proteins were bound to the glutathione-Sepharose beads,
incubated with the individual T7·Tag-Cbl proteins, and then, after
extensive washing, the bound T7·Tag-Cbl proteins were quantified as
described under "Experimental Procedures." As in the filter binding
assay, GST-Cbl-C half was found to associate with T7·Tag-Cbl-C half
and the shorter variant T7·Tag-Cbl-Ac + LZ (Fig.
5, top and bottom
panels, lane 2), both of which contain
the leucine zipper domain, but not with the counterparts lacking the
leucine zipper, T7·Tag-Cbl-C half,
LZ and T7·Tag-Cbl-Ac (Fig. 5,
top and bottom panels, lane
6). Similarly, the association was abolished when the
immobilized GST-Cbl fusion protein lacked the leucine zipper (Fig. 5,
lane 7 of both panels). The binding of
the T7-tagged Cbl proteins containing the leucine zipper domain to the
immobilized GST-Cbl-C half could be competitively displaced by
increasing amounts of T7·Tag-Cbl-LZ protein (Fig. 5, top
and bottom panels, compare lane
2 with lanes 3-5). Thus, Cbl fusion proteins can associate in vitro in a leucine
zipper-dependent manner.
|
c-Cbl Dimerization in HEK293 Cells Is Dependent upon the Leucine
Zipper--
In order to determine whether Cbl homodimerization occurs
in vivo, cells that stably expressed N-terminal EGFP-tagged
Cbl-FL were transiently transfected with N-terminal Myc-tagged Cbl-FL and Cbl-
LZ. EGFP-tagged Cbl was then immunoprecipitated from total
cell lysates, and the immune complexes were Western blotted for the
presence of Myc-Cbl-FL or Myc-Cbl-
LZ. As can be seen in Fig.
6, a protein of approximately 120 kDa,
which corresponds to the correct size for Myc-Cbl-FL, was detected in
anti-GFP immunoprecipitates from cells expressing Myc-Cbl-FL, while no
Myc-tagged Cbl-
LZ could be detected in immunoprecipitates from cells
expressing that protein. Similar amounts of EGFP-Cbl-FL were
immunoprecipitated from all lysates, and similar amounts of Myc-Cbl-FL
and Myc-Cbl-
LZ were detected in the appropriate total cell lysates.
These data demonstrate that c-Cbl homodimerizes in mammalian cells in a
leucine zipper-dependent manner.
|
The Leucine Zipper Is Required for Efficient Tyrosine
Phosphorylation of c-Cbl and Its Association with the EGFR following
Stimulation with EGF--
The stimulation of growth factor receptors,
such as the EGFR, induces the rapid tyrosine phosphorylation of c-Cbl
and the recruitment of c-Cbl to the activated receptors (6). To test whether these events are influenced by the dimerization of c-Cbl, HEK
293 cells were transiently transfected with vector alone, Myc-Cbl-FL,
or Myc-Cbl-
LZ and, after 36-h serum starvation, stimulated with 100 ng/ml EGF or vehicle for 3 min. Western blot analysis of total cell
lysates showed equivalent levels of expression of Myc-tagged Cbl-FL and
Cbl-
LZ in the appropriate samples (Fig. 7A, bottom
panel). In all three lysates, stimulation of the EGFR resulted in a dramatic and comparable increase in tyrosine
phosphorylation of proteins over a wide range of molecular weights,
including the 110-200-kDa region (Fig. 7A, top
panel). A strong 120-kDa band was apparent in the lysates
from stimulated cells that had been transfected with Cbl-FL but was not
present in control cell lysates or in Cbl-
LZ-expressing cells,
suggesting that Cbl-FL, but not Cbl-
LZ, was being efficiently
tyrosine-phosphorylated. To further analyze the phosphorylation and
receptor association of Cbl, Myc-tagged Cbl proteins were
immunoprecipitated, and the immune complexes were blotted with
antibodies to phosphotyrosine, Myc, and the EGFR (Fig. 7B).
This analysis confirmed that EGF-induced tyrosine phosphorylation of
Cbl-
LZ was markedly decreased, relative to the phosphorylation of
Cbl-FL. In addition, the amount of activated EGFR (23) was greatly
reduced in the Cbl-
LZ sample (Fig. 7B, top
panel), despite the fact that the induction of EGFR
phosphorylation by EGF was similar in all lysates (Fig. 7A,
top panel). Blotting the anti-Myc
immunoprecipitates with anti-EGFR (Fig. 7B,
bottom panel) confirmed that markedly less of the
170-kDa EGFR was associated with Cbl-
LZ than with Cbl-FL. Thus, the
leucine zipper-mediated dimerization of c-Cbl appears to be required
for the maximally efficient tyrosine phosphorylation of c-Cbl and for
the effective binding of c-Cbl to the activated receptor.
|
| |
DISCUSSION |
|---|
|
|
|---|
c-Cbl has been previously shown to interact with a wide range of
signaling proteins through the engagement of its PTB domain, proline-rich domain and phosphotyrosine- and phosphoserine-containing motifs (2, 7, 9, 18, 20, 22, 23, 25). With the exception of the PTB
domain, the other known functional binding sites are localized within
the C-terminal half of the molecule. In this study, we demonstrated
that another domain in the C-terminal half of c-Cbl, previously
identified as a putative leucine zipper domain, mediates the formation
of c-Cbl homodimers both in vitro and in vivo.
Furthermore, we found that the leucine zipper is the only domain of the
Cbl molecule that is absolutely required in order for the homodimer
interaction to occur. (A RING finger motif has been identified in the
N-terminal half of the molecule, and while it may participate in the
associations of c-Cbl with other proteins, it does not mediate c-Cbl
homodimerization.) Several lines of evidence support these conclusions.
First, in the two-hybrid assay and in HEK293 cells, deletion of the
C-terminal leucine zipper domain was sufficient to abolish
homodimerization (Fig. 2), and a Cbl variant lacking the leucine zipper
was unable to interact with the full-length Cbl (Figs. 3 and 6).
Second, a Cbl mutant carrying extensive truncations of N-terminal
sequences and composed solely of the acidic and leucine zipper domains
retained the ability to dimerize with the full-length Cbl in the
two-hybrid system (Fig. 3) and with the C-terminal half of Cbl in the
in vitro binding assays (Figs. 4 and 5). Both interactions
could be abolished by deleting the leucine zipper domain. Third, the in vitro dimerization of the C-terminal half of Cbl with
itself and with the variant composed of the acidic and leucine zipper domains could be competitively disrupted by a recombinant protein containing little more than the leucine zipper domain (Fig. 5). However, although the leucine zipper domain is indispensable for Cbl
homodimerization, and sequences upstream of the leucine zipper domain
do not themselves show the ability to dimerize, quantitative analysis
of the two-hybrid assay suggests that these upstream sequences may
contribute to the strength of the homodimerization of the full-length
Cbl molecules. Thus, the full-length Cbl homodimer induced higher
-galactosidase activity than did the homodimer of Cbl that lacked
the acidic domain (Fig. 2), and the homodimerization of the full-length
Cbl was stronger than the interaction of full-length Cbl with either
the C-terminal half of Cbl or the fragment composed of the acidic and
leucine zipper domains (Fig. 3). Moreover, in the in vitro
binding studies with fusion proteins, the interaction of the C-half of
Cbl with itself or with the fusion protein containing the acidic and
leucine zipper domains was much stronger than the association of Cbl
C-half with a short fragment comprised solely of the leucine zipper
domain (Fig. 4).
As noted under "Results," fusion proteins of the LexA DNA binding
domain with the C-terminal half of Cbl and deletion variants thereof
behaved as activators of transcription in the two-hybrid assay in the
presence of the VP16 activation domain alone and for this reason could
not be tested for the formation of dimers with the interacting
partners. Detailed deletion analysis indicated that the sequences
contained within the acidic domain of Cbl are in large part responsible
for this effect (data not shown). Similar transactivation by acidic
sequences in other proteins has been reported (38). The absence of such
an effect with the full-length Cbl-LexA fusion suggests that the acidic
domain may be hidden inside the folded protein structure of the
full-length molecule and that it reveals its transactivation potential
only after removal of the sequences comprising the N-terminal half of
Cbl. Furthermore, the dimer of full-length Cbl with the Cbl that lacked
the acidic domain (Cbl-
Ac) induced higher
-galactosidase activity
than the full-length Cbl homodimer (Fig. 3). This increased
transcription activation might be the result of the exposure of the
acidic domain of the full-length Cbl molecule in the dimer formed
between Cbl-FL and Cbl-
Ac.
The leucine zipper domain is an
-helical structure formed by several
heptad repeats of hydrophobic residues, usually leucine and isoleucine,
that is commonly found in nuclear transcription factors, and its role
in promoting the homo- and heterodimerization of these proteins has
been well documented (39, 40). Leucine zipper domains have also been
identified in many other proteins, mostly protein kinases and
cytoskeletal proteins, but their function in these proteins has been
less extensively examined. Leucine zipper-mediated homodimerization of
some chimeric receptor tyrosine kinases, which are formed as a result
of chromosomal rearrangements, is considered to be responsible for
their oncogenic activity (41, 42). Moreover, the leucine
zipper-dependent homodimerization of both
cGMP-dependent protein kinase and ZIP kinase, a
serine/threonine kinase, is necessary for their activity (43, 44). Some
other serine/threonine protein kinases such as fatty acid-activated protein kinase N and members of the mixed lineage kinase family also
contain leucine zipper motifs, but the function of the domain in these
proteins has not been elucidated (45-47). In addition to kinases, many
cytoskeletal proteins, including myosin, keratin,
-spectrin,
microtubule-associated protein, vimentin, and kinectin, have been found
to contain leucine zipper motifs (48-51). In the few cases where the
function of a leucine zipper in these proteins has been characterized,
it also mediates homo- or heterodimerization. Thus, the cytoskeletal,
sperm-specific outer dense fiber proteins, Odf27 and Odf84, have
been shown to heterodimerize through the engagement of their leucine
zipper domains (52), and dystrophin is capable of interacting with
troponin T via its leucine zipper domain (53). Finally, a recent report
on AFAP-110 (actin filament-associated protein, 110 kDa) demonstrates
that its leucine zipper structure might play an important role in the
protein's self-association, its cellular localization, and its ability
to interact with actin filaments (48).
In the case of c-Cbl, our data show that the deletion of the leucine
zipper and the resulting loss of Cbl dimerization lead to decreased
EGF-induced tyrosine phosphorylation of c-Cbl and c-Cbl-EGFR
association, indicating that the leucine zipper-mediated dimerization
of c-Cbl has functional significance. Although two tyrosine residues
(at positions 871 and 869) are deleted in the Cbl-
LZ protein, it is
unlikely that the absence of these two tyrosine residues would cause
such a large decrease in the total tyrosine phosphorylation of c-Cbl in
response to EGF, since the major c-Cbl tyrosine phosphorylation sites
in pervanadate-treated cells are N-terminal to the leucine zipper
domain at positions 700, 731, and 774 (54). It is also unlikely that
the lower amount of Cbl-
LZ-associated EGFR is the result of the
decreased tyrosine phosphorylation of Cbl-
LZ, since neither of the
known mechanisms of c-Cbl-EGFR association (the direct binding of the
c-Cbl PTB domain to a phosphotyrosine on the EGFR (23) and the
Grb2-mediated indirect association (55)) involves phosphotyrosine
residues on c-Cbl. Rather, both the diminished tyrosine phosphorylation of Cbl-
LZ and the reduced association of Cbl-
LZ with the EGFR are
likely to be the consequences of the inability of Cbl-
LZ to
dimerize. The simplest hypothesis is that the lack of dimerization would probably result in the incorporation of only half as many c-Cbl
molecules into the EGFR-associated signaling complex, which could in
turn result in half the amount of c-Cbl being phosphorylated by the
activated EGFR. However, both the level of Cbl-
LZ phosphorylation and the amount of EGFR that is associated with Cbl-
LZ appear to be
less than half of the amounts observed with Cbl-FL. It may therefore be
that the direct association of c-Cbl with the EGFR is stronger for the
Cbl dimer than for the monomer or that the presence of two sets of
binding domains on the c-Cbl dimer allows the formation of more
indirect links (for example, by Grb2), which stabilize the interaction.
c-Cbl is, to our knowledge, the first adaptor protein that is demonstrated to have the ability to homodimerize through a leucine zipper-dependent mechanism. Nevertheless, the homodimerization of adaptor and scaffold proteins through other types of binding domains has been previously reported. Dimerization of Ste 5, a scaffold protein for the components of the mitogen-activated protein kinase cascade in Saccharomyces cerevisiae, is mediated by the RING-H2 domain (in contrast to the lack of involvement of the c-Cbl RING finger in its homodimerization) and is essential for the regulation of the pheromone mating response (56, 57). Members of the ubiquitous 14-3-3 family of eukaryotic adaptor proteins, which interact with numerous signaling molecules with distinct functions, exist and act both as homodimers and as heterodimers with other isoforms within the family (58, 59). The recently identified multidomain adaptor protein HEF-1, which is involved in cell adhesion-related signaling pathways (60), homodimerizes via a helix-loop-helix domain that is also required for the biological activity of HEF-1 protein.3 Finally, members of the Bcl-2 family of regulators of apoptosis, which function both as ion channels and as adaptor/docking proteins, are known to homodimerize and heterodimerize with other family members, a property that is critical for the biological functions of these proteins (61).
Thus, homo- and heterodimerization of adaptor proteins occur within a variety of signal transduction pathways and participate in the regulation of several molecular assemblies. In the case of an adaptor protein such as c-Cbl, the ability to homodimerize might have several consequences for its activity and biological function. Dimeric adaptors could, as suggested previously (1), function as molecular bridges to juxtapose proteins that do not associate directly and/or that bind to the same domain(s) within the adaptor. Dimer formation could also uncover or mask specific functional domains of c-Cbl as a result of conformational changes that might be induced by dimerization. For example, accessibility of the major tyrosine phosphorylation sites, located within the acidic domain in close proximity to the leucine zipper (54), could be altered, thereby changing the kinetics of phosphorylation or dephosphorylation and/or affecting Cbl's association with other signaling proteins (another possible explanation of our data). In addition, if dimerization is regulated, for example by tyrosine phosphorylation, changes in the relative amounts of the monomer and dimer could thus serve as a mechanism to modulate c-Cbl activities and functions, such as c-Cbl's known negative regulatory effect on some protein kinases. It will thus be important to understand how formation of the homodimer is controlled.
Finally, the presence of a functional leucine zipper opens the possibility that Cbl heterodimerizes with other leucine zipper-containing proteins, such as the numerous serine/threonine kinases and cytoskeletal proteins discussed earlier, thereby increasing enormously the number of potential Cbl binding partners. Such interactions could be crucial to Cbl's normal function. For example, it is possible that the absence of the leucine zipper allows v-Cbl to translocate to the nucleus rather than maintaining the normal cytoplasmic location of c-Cbl. Identifying the molecules that specifically interact with Cbl through the leucine zipper-mediated mechanism will be an important goal of future studies.
In conclusion, we have shown that the putative leucine zipper domain at
the C terminus of c-Cbl mediates the formation of homodimers and that
the homodimerization of c-Cbl is required for the efficient tyrosine
phosphorylation of this protein and its association with the EGFR.
Homodimerization may be important for c-Cbl's association with other
signaling proteins in the cell as well. Further investigation of the
role of the leucine zipper and c-Cbl homodimerization are thus likely
to provide additional important insights into the biology of this
signaling protein.
| |
ACKNOWLEDGEMENTS |
|---|
We thank B. Datta for help with the yeast two-hybrid assay, S. Hollenberg for providing yeast plasmids and yeast strains, W. Langdon for the gift of human c-Cbl cDNA, M. Sahni for providing pBK-CMV-Myc vector, and J. B. Levy for helpful discussions. We are grateful to W. C. Horne for valuable suggestions and help with the preparation of this manuscript.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant AR42927 (to R. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Depts. of Cell Biology
and Orthopedics, Yale University School of Medicine, 333 Cedar St., New
Haven, CT 06510. Tel.: 203-785-4150; Fax: 203-785-2744; E-mail:
roland.baron@yale.edu.
2 Yokouchi, M., Houghton, A., Kondo, T., Bartkiewicz, M., Horne, W. C., Zhang, H., Yoshimura, A., and Baron, R. (1999) J. Biol. Chem. in press.
3 S. Law and E. Golemis, personal communication.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
EGF, epidermal
growth factor;
EGFR, EGF receptor;
PTB, phosphotyrosine-binding;
GST, glutathione S-transferase;
GFP, green fluorescent protein;
EGFP, enhanced GFP;
-MEM,
-modified Eagle's minimum essential
medium;
mAb, monoclonal antibody;
mRIPA, modified radioimmune
precipitation assay.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Pawson, T.,
and Scott, J. D.
(1997)
Science
278,
2075-2080 |
| 2. |
Reedquist, K. A.,
Fukazawa, T.,
Panchamoorthy, G.,
Langdon, W. Y.,
Shoelson, S. E.,
Druker, B. J.,
and Band, H.
(1996)
J. Biol. Chem.
271,
8435-8442 |
| 3. |
Smit, L.,
Van der Horst, G.,
and Borst, J.
(1996)
J. Biol. Chem.
271,
8564-8569 |
| 4. |
Gesbert, F.,
Garbay, C.,
and Bertoglio, J.
(1998)
J. Biol. Chem.
273,
3986-3993 |
| 5. | Blake, T. J., Shapiro, M., Morse, H. C., III, and Langdon, W. Y. (1991) Oncogene 6, 653-657[Medline] [Order article via Infotrieve] |
| 6. | Langdon, W. Y. (1995) Aust. N. Z. J. Med. 25, 859-864[Medline] [Order article via Infotrieve] |
| 7. |
Tanaka, S.,
Neff, L.,
Baron, R.,
and Levy, J. B.
(1995)
J. Biol. Chem.
270,
14347-14351 |
| 8. | Chin, H., Saito, T., Arai, A., Yamamoto, K., Kamiyama, R., Miyasaka, N., and Miura, O. (1997) Biochem. Biophys. Res. Commun. 239, 412-417[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Fukazawa, T.,
Reedquist, K. A.,
Trub, T.,
Soltoff, S.,
Panchamoorthy, G.,
Druker, B.,
Cantley, L.,
Shoelson, S. E.,
and Band, H.
(1995)
J. Biol. Chem.
270,
19141-19150 |
| 10. |
Panchamoorthy, G.,
Fukazawa, T.,
Miyake, S.,
Soltoff, S.,
Reedquist, K.,
Druker, B.,
Shoelson, S.,
Cantley, L.,
and Band, H.
(1996)
J. Biol. Chem.
271,
3187-3194 |
| 11. | Uddin, S., Gardziola, C., Dangat, A., Yi, T., and Platanias, L. C. (1996) Biochem. Biophys. Res. Commun. 225, 833-838[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Ojaniemi, M.,
Martin, S. S.,
Dolfi, F.,
Olefsky, J. M.,
and Vuori, K.
(1997)
J. Biol. Chem.
272,
3780-3787 |
| 13. |
Anderson, S. M.,
Burton, E. A.,
and Koch, B. L.
(1997)
J. Biol. Chem.
272,
739-745 |
| 14. | Ribon, V., and Saltiel, A. R. (1997) Biochem. J. 324, 839-845 |
| 15. |
Hunter, S.,
Koch, B. L.,
and Anderson, S. M.
(1997)
Mol. Endocrinol.
11,
1213-1222 |
| 16. | Jain, S. K., Langdon, W. Y., and Varticovski, L. (1997) Oncogene 14, 2217-2228[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
Buday, L.,
Khwaja, A.,
Sipeki, S.,
Faragó, A.,
and Downward, J.
(1996)
J. Biol. Chem.
271,
6159-6163 |
| 18. |
Donovan, J. A.,
Wange, R. L.,
Langdon, W. Y.,
and Samelson, L. E.
(1994)
J. Biol. Chem.
269,
22921-22924 |
| 19. | Sattler, M., Salgia, R., Okuda, K., Uemura, N., Durstin, M. A., Pisick, E., Xu, G., Li, J. L., Prasad, K. V., and Griffin, J. D. (1996) Oncogene 12, 839-846[Medline] [Order article via Infotrieve] |
| 20. | Meisner, H., Conway, B. R., Hartley, D., and Czech, M. P. (1995) Mol. Cell. Biol. 15, 3571-3578[Abstract] |
| 21. | Marengère, L. E. M., Mirtsos, C., Kozieradzki, I., Veillette, A., Mak, T. W., and Penninger, J. M. (1997) J. Immunol. 159, 70-76[Abstract] |
| 22. |
Lupher, M. L., Jr.,
Reedquist, K. A.,
Miyake, S.,
Langdon, W. Y.,
and Band, H.
(1996)
J. Biol. Chem.
271,
24063-24068 |
| 23. | Thien, C. B., and Langdon, W. Y. (1997) Oncogene 14, 2239-2249[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Bonita, D. P., Miyake, S., Lupher, M. L., Jr., Langdon, W. Y., and Band, H. (1997) Mol. Cell. Biol. 17, 4597-4610[Abstract] |
| 25. |
Liu, Y. C.,
Liu, Y. H.,
Elly, C.,
Yoshida, H.,
Lipkowitz, S.,
and Altman, A.
(1997)
J. Biol. Chem.
272,
9979-9985 |
| 26. |
Rivero-Lezcano, O. M.,
Sameshima, J. H.,
Marcilla, A.,
and Robbins, K. C.
(1994)
J. Biol. Chem.
269,
17363-17366 |
| 27. |
Marcilla, A.,
Rivero-Lezcano, O. M.,
Agarwal, A.,
and Robbins, K. C.
(1995)
J. Biol. Chem.
270,
9115-9120 |
| 28. |
Cory, G. O. C.,
Lovering, R. C.,
Hinshelwood, S.,
MacCarthy-Morrogh, L.,
Levinsky, R. J.,
and Kinnon, C.
(1995)
J. Exp. Med.
182,
611-615 |
| 29. |
Yoon, C. H.,
Lee, J.,
Jongeward, G. D.,
and Sternberg, P. W.
(1995)
Science
269,
1102-1105 |
| 30. | Meisner, H., Daga, A., Buxton, J., Fernández, B., Chawla, A., Banerjee, U., and Czech, M. P. (1997) Mol. Cell. Biol. 17, 2217-2225[Abstract] |
| 31. | Thien, C. B., and Langdon, W. Y. (1997) Oncogene 15, 2909-2919[CrossRef][Medline] [Order article via Infotrieve] |
| 32. |
Ota, Y.,
and Samelson, L. E.
(1997)
Science
276,
418-420 |
| 33. |
Lupher, M. L., Jr.,
Songyang, Z.,
Shoelson, S. E.,
Cantley, L. C.,
and Band, H.
(1997)
J. Biol. Chem.
272,
33140-33144 |
| 34. | Ausubel, F. M., Brent, R., Kingston, D. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1991) Current Protocols in Molecular Biology , John Wiley & Sons, Inc., New York |
| 35. | Vojtek, A. B., Hollenberg, S. M., and Cooper, J. A. (1993) Cell 74, 205-214[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Vojtek, A. B., and Hollenberg, S. M. (199 |